DJI46,208.47+1.38%
GDAXI22,653.86+1.22%
GSPC6,581.00+1.15%
HSI24,382.47-3.54%
IXIC21,946.76+1.38%
N22551,515.49-3.48%
AAPL251.49+1.41%
AMZN210.14+2.32%
CL89.07+1.07%
EURUSD1.1616+0.35%
GBPUSD1.3431+0.64%
GC4,409.60+0.05%
GOOG299.02+0.08%
JPM289.91+1.17%
META604.06+1.75%
MSFT383.00+0.30%
NVDA175.64+1.57%
TSLA380.85+3.50%
DJI46,208.47+1.38%
GDAXI22,653.86+1.22%
GSPC6,581.00+1.15%
HSI24,382.47-3.54%
IXIC21,946.76+1.38%
N22551,515.49-3.48%
AAPL251.49+1.41%
AMZN210.14+2.32%
CL89.07+1.07%
EURUSD1.1616+0.35%
GBPUSD1.3431+0.64%
GC4,409.60+0.05%
GOOG299.02+0.08%
JPM289.91+1.17%
META604.06+1.75%
MSFT383.00+0.30%
NVDA175.64+1.57%
TSLA380.85+3.50%
DJI46,208.47+1.38%
GDAXI22,653.86+1.22%
GSPC6,581.00+1.15%
HSI24,382.47-3.54%
IXIC21,946.76+1.38%
N22551,515.49-3.48%
AAPL251.49+1.41%
AMZN210.14+2.32%
CL89.07+1.07%
EURUSD1.1616+0.35%
GBPUSD1.3431+0.64%
GC4,409.60+0.05%
GOOG299.02+0.08%
JPM289.91+1.17%
META604.06+1.75%
MSFT383.00+0.30%
NVDA175.64+1.57%
TSLA380.85+3.50%
CYBERETIKAGLOBAL FINANCIAL INTELLIGENCE
LIVE
USA The Motley Fool EN

Here's How Much Upside Eli Lilly Stock Has, According to Analysts

Eli Lilly's stock has been receiving many upgrades after posting strong quarterly results in February.

Mar 23, 2026 &03002323202631; 13:00 UTC www.fool.com
Read original on www.fool.com ↗
→
Neutral impact
Sentiment score: +15/100
Moderate impact Short-term (days)
WHAT THIS MEANS
Eli Lilly received multiple analyst upgrades following strong Q4 2024 results in February, suggesting market confidence in the company's fundamentals. However, the stock has likely already priced in positive sentiment given the recent rally, limiting near-term upside.
AI CONFIDENCE
72% High
SENTIMENT GAUGE
NEWS POWER SCORE
AFFECTED ASSETS
↑
Eli Lilly
LLYStock
Expected to rise
Analyst upgrades post strong earnings, but stock likely already reflects positive sentiment; upside may be limited in near term
⇅
S&P 500
^GSPCIndex
High volatility expected
Healthcare/pharma sector strength could support broader market, but dependent on macro conditions
PRICE HISTORY
Loading chart...
⚡ SUGGESTED ACTION
Wait for pullback or consolidation before initiating long positions. The upgrades are backward-looking; focus on forward guidance and pipeline catalysts rather than chasing momentum. Monitor for any negative macro headwinds affecting healthcare sector valuations.
KEY SIGNALS
Multiple analyst upgrades post-earningsStrong quarterly results in FebruaryPotential valuation already elevatedPromotional headline without specific price targets mentioned
SECTORS INVOLVED
HealthcarePharmaceuticalsBiotechnology
Analysis generated on Mar 23, 2026 at 19:36 UTC
Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by The Motley Fool. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

RELATED INTELLIGENCE

Eli Lilly and Company (LLY) Expands Zepbound Access as Pricing Reforms Boost Long-Term Growth Outlook
Yahoo Finance Mar 22, 16:53 Neutral
Eli Lilly and Company (LLY) Announces Positive Topline Results From the Phase 3 ADorable-1 Trial
Yahoo Finance Mar 20, 20:38 Neutral
4 stocks to watch on Friday: LLY, AMZN, NVS, UL
Seeking Alpha Mar 20, 12:46 Neutral
Lilly trades flat as adverse events overshadow trial win for next-gen obesity drug
Seeking Alpha Mar 19, 14:28 Neutral
Why Weight-Loss Contender Structure Therapeutics Just Shot Skyward
Investors Business Daily Mar 16, 13:13 Positive